Since launching in April 2021, Mestag says that it has progressed “a pipeline of sophisticated first-in-class antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.” However, it has also built the reversing activated fibroblast technology (RAFT) platform to identify novel drug targets and it is the latter that has caught the eye of Merck.
The big pharma has the option to license one or more targets, up to a prespecified number, and will be...
